Biome Australia (ASX: $BIO) Key Facts

Biome Australia (ASX: $BIO) is a certified B Corporation focused on becoming a global leader in the complementary medicine industry. The company, listed on the ASX since November 2021, has achieved significant milestones including a 76.5% sales growth in FYTD24, reaching over 5000 distribution points, and reporting positive EBITDA in Q3 FY24. Biome Australia's flagship range, Activated Probiotics, has shown strong performance in key pharmacy chains and practitioner markets.

Executive Commentary

Blair Norfolk, CEO & Managing Director, highlighted the company's achievements, stating, 'We are pleased with the strong sales growth and the positive EBITDA in Q3 FY24. Our focus on expanding distribution points and the performance of our Activated Probiotics range in pharmacy and practitioner markets has been instrumental in driving our revenue. We remain committed to our mission of preventing disease, improving health outcomes, and making our products accessible to all.'

Summary

Biome Australia (ASX: $BIO) has demonstrated robust sales growth, reaching $9.22m in FYTD24, with a forecast of $12.5m in sales for FY24. The company's focus on expanding distribution points, achieving positive EBITDA in Q3 FY24, and the strong performance of its Activated Probiotics range in pharmacy and practitioner markets indicates a positive outlook. With ongoing clinical trials and a commitment to corporate social and environmental impact, Biome Australia is well-positioned to continue its growth trajectory and capture opportunities in both domestic and international markets.